FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jules Schwartz

Research Profile

Chemicals & Drugs

Procedures

Physiology

Drug Interactions

Concepts & Ideas

Phenomena

Metabolic Clearance Rate

Co-author Network

Publications

TOP 3
aimee dallob; Jan N De Hoon; Inge De Lepeleire; Victor Dishy; Amy O Johnson-Levonas; Walter K Kraft; Julie Mabalot Luk; Wen-Lin Luo; Waldemar Radziszewski; Lisa Ratcliffe; Jules I Schwartz; Anne Van Hecken; John A Wagner; Eseng Lai
The effects of laropiprant, a selective prostaglandin D₂ receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin.
Eseng Lai; Jules I Schwartz; aimee dallob; Patricia Jumes; Fang Liu; Walter K Kraft; Jane Royalty; Jeffrey A Chodakewitz; Christine McCrary Sisk; Waldemar Radziszewski; John A Wagner
Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects.
Jules I Schwartz; Fang Liu; Ying-Hong Wang; Barnali Pramanik; Amy O Johnson-Levonas; Maria J Gutierrez; Eseng Lai; John A Wagner
Effect of laropiprant, a PGD2 receptor 1 antagonist, on estradiol and norgestimate pharmacokinetics after oral contraceptive administration in women.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jules Schwartz (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: aimee dallob; Jan N De Hoon; Inge De Lepeleire; Victor Dishy; Amy O Johnson-Levonas; Walter K Kraft; Julie Mabalot Luk; Wen-Lin Luo; Waldemar Radziszewski; Lisa Ratcliffe; Jules I Schwartz; Anne Van Hecken; John A Wagner; Eseng Lai
The effects of laropiprant, a selective prostaglandin D₂ receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin.
Platelets 2011;22(7):495-503.
2010: Eseng Lai; Jules I Schwartz; aimee dallob; Patricia Jumes; Fang Liu; Walter K Kraft; Jane Royalty; Jeffrey A Chodakewitz; Christine McCrary Sisk; Waldemar Radziszewski; John A Wagner
Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects.
Platelets 2010;21(3):191-8.
2009: Jules I Schwartz; Fang Liu; Ying-Hong Wang; Barnali Pramanik; Amy O Johnson-Levonas; Maria J Gutierrez; Eseng Lai; John A Wagner
Effect of laropiprant, a PGD2 receptor 1 antagonist, on estradiol and norgestimate pharmacokinetics after oral contraceptive administration in women.
American journal of therapeutics 2009;16(6):487-95.
2009: Jules I Schwartz; Nancy G B Agrawal; Peggy H Wong; Jutta Miller; Kenneth Bachmann; Thomas C Marbury; David Hoelscher; Paul F Cavanaugh; Keith M Gottesdiener
Examination of the effect of increasing doses of etoricoxib on oral methotrexate pharmacokinetics in patients with rheumatoid arthritis.
Journal of clinical pharmacology 2009;49(10):1202-9.
2009: Jules I Schwartz; Fang Liu; Mark Stroh; Adrianna Gipson; Amy O Johnson-Levonas; Kenneth C Lasseter; Eseng Lai; John A Wagner
Influence of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the pharmacokinetics and pharmacodynamics of warfarin.
American journal of therapeutics 2009;16(3):215-23.
2009: Jules I Schwartz; Mark Stroh; Bing Gao; Fang Liu; Kimberly Rosko; Stefan Zajic; Alan J Meehan; Jon Ruckle; Eseng Lai; John A Wagner
Effects of laropiprant, a selective prostaglandin D(2) receptor 1 antagonist, on the pharmacokinetics of rosiglitazone.
Cardiovascular therapeutics 2009;27(4):239-45.
2009: Jules I Schwartz; Stephanie Dunbar; Jinyu Yuan; Susie Li; Deborah L Miller; Kim Rosko; Amy O Johnson-Levonas; Kenneth C Lasseter; John A Wagner
Influence of taranabant, an orally active, highly selective, potent cannabinoid-1 receptor (CB1R) inverse agonist, on ethinyl estradiol and norelgestromin plasma pharmacokinetics.
Journal of clinical pharmacology 2009;49(1):72-9.
2008: Jules I Schwartz; Nancy G B Agrawal; Martin Wehling; Bret J Musser; Carol P Gumbs; Nicole Michiels; Marina De Smet; John A Wagner
Evaluation of the pharmacokinetics of digoxin in healthy subjects receiving etoricoxib.
British journal of clinical pharmacology 2008;66(6):811-7.
2008: Jules I Schwartz; Stephanie Dunbar; Jinyu Yuan; Susie Li; Adrianna Gipson; Kim Rosko; Amy O Johnson-Levonas; Kenneth C Lasseter; Carol Addy; Aubrey S Stoch; John A Wagner
Influence of taranabant, a cannabinoid-1 receptor inverse agonist, on pharmacokinetics and pharmacodynamics of warfarin.
Advances in therapy 2008;25(11):1175-90.
2008: Jules I Schwartz; aimee dallob; Patrick J Larson; Omar F Laterza; Jutta Miller; Jane Royalty; Karen Snyder; Derek L Chappell; Deborah Hilliard; Mary E Flynn; Paul F Cavanaugh; John A Wagner
Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects.
Journal of clinical pharmacology 2008;48(6):745-54.
2007: Jules I Schwartz; Chau Thach; Kenneth C Lasseter; Jutta Miller; David Hreniuk; Deborah Hilliard; Karen Snyder; Barry J Gertz; Keith M Gottesdiener
Effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs on urinary sodium excretion, blood pressure, and other renal function indicators in elderly subjects consuming a controlled sodium diet.
Journal of clinical pharmacology 2007;47(12):1521-31.
2007: Jules I Schwartz; Nancy G B Agrawal; Uma A Kher; Marina DeSmet; Paul F Cavanaugh; Michel Guillaume; David L Ebel; Shelia A Merschman; John A Wagner
Lack of effect of antacids on single-dose pharmacokinetics of etoricoxib.
Journal of clinical pharmacology 2007;47(10):1342-6.
2007: Jules I Schwartz; Nancy G B Agrawal; Alan H Hartford; Josee Cote; Thomas L Hunt; Rene Verbesselt; Dane R Eckols; Keith M Gottesdiener
The effect of etoricoxib on the pharmacodynamics and pharmacokinetics of warfarin.
Journal of clinical pharmacology 2007;47(5):620-7.
2007: Jules I Schwartz; Paul Kotey; James R Fricke; Keith M Gottesdiener
MK-0703 (a cyclooxygenase-2 inhibitor) in acute pain associated with dental surgery: a randomized, double-blind, placebo- and active comparator-controlled dose-ranging study.
American journal of therapeutics 2007;14(1):13-9.
2004: Nancy G B Agrawal; Catherine Z Matthews; Ralph S Mazenko; Walter F Kline; Eric J Woolf; Arturo G Porras; Leslie A Geer; Peggy H Wong; Meehung Cho; Josee Cote; Thomas C Marbury; Jack W Moncrief; Harry Alcorn; Suzanne Swan; Marshall Sack; Richard A Robson; Petty Kevin; Jules I Schwartz; Keith M Gottesdiener
Pharmacokinetics of etoricoxib in patients with renal impairment.
Journal of clinical pharmacology 2004;44(1):48-58.
2003: Kenneth Bachmann; Donald White; Luis Jauregui; Jules I Schwartz; Nancy G B Agrawal; Ralph S Mazenko; Patrick J Larson; Arturo G Porras
An evaluation of the dose-dependent inhibition of CYP1A2 by rofecoxib using theophylline as a CYP1A2 probe.
Journal of clinical pharmacology 2003;43(10):1082-90.
2003: Nancy G B Agrawal; Arturo G Porras; Catherine Z Matthews; Mark J Rose; Eric J Woolf; Bret J Musser; Andrea L Dynder; Kathryn E Mazina; Kenneth C Lasseter; Thomas L Hunt; Jules I Schwartz; Jacqueline B McCrea; Keith M Gottesdiener
Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man.
Journal of clinical pharmacology 2003;43(3):268-76.
2003: Jules I Schwartz; Saurabh Mukhopadhyay; Arturo G Porras; Kala-Jyoti Viswanathan-Aiyer; Sherilyn Adcock; David L Ebel; Barry J Gertz
Effect of rofecoxib on prednisolone and prednisone pharmacokinetics in healthy subjects.
Journal of clinical pharmacology 2003;43(2):187-92.
2003: Jules I Schwartz; Patrick J Larson; Arturo G Porras; Kala-Jyoti Viswanathan-Aiyer; Nancy G B Agrawal; Kenneth C Lasseter; Ralph S Mazenko; Sheila A Merschman; Barry J Gertz
Pharmacokinetic evaluation of rofecoxib : comparison of tablet and suspension formulations.
Clinical drug investigation 2003;23(8):503-9.
2002: Jules I Schwartz; K Vandormael; M P Malice; R N Kalyani; Kenneth C Lasseter; G B Holmes; Barry J Gertz; Keith M Gottesdiener; M Laurenzi; K-J Redfern; K Brune
Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet.
Clinical pharmacology and therapeutics 2002;72(1):50-61.
2002: Rita A Halpin; Arturo G Porras; Leslie A Geer; Margaret R Davis; Donghui Cui; George A Doss; Eric J Woolf; Donald G Musson; Catherine Matthews; Ralph S Mazenko; Jules I Schwartz; Kenneth C Lasseter; Kamlesh P Vyas; Thomas A Baillie
The disposition and metabolism of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in human subjects.
Drug metabolism and disposition: the biological fate of chemicals 2002;30(6):684-93.
2002: Jules I Schwartz; Peggy H Wong; Arturo G Porras; David L Ebel; Thomas R Hunt; Barry J Gertz
Effect of rofecoxib on the pharmacokinetics of chronically administered oral contraceptives in healthy female volunteers.
Journal of clinical pharmacology 2002;42(2):215-21.
2001: Jules I Schwartz; Nancy G B Agrawal; Peggy H Wong; Kenneth Bachmann; Arturo G Porras; Jutta L Miller; David L Ebel; Marshall Sack; G B Holmes; Jan S Redfern; Barry J Gertz
Lack of pharmacokinetic interaction between rofecoxib and methotrexate in rheumatoid arthritis patients.
Journal of clinical pharmacology 2001;41(10):1120-30.
2001: Cuyue Tang; Magang Shou; Thomas H Rushmore; Qin Mei; Punam Sandhu; Eric J Woolf; Mark J Rose; A Gelmann; Howard E Greenberg; Inge De Lepeleire; Anne Van Hecken; Paul De Schepper; David L Ebel; Jules I Schwartz; A David Rodrigues
In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics.
Pharmacogenetics 2001;11(3):223-35.
2001: Jules I Schwartz; M De Smet; Patrick J Larson; Rene Verbesselt; David L Ebel; R Lins; S Lens; Arturo G Porras; Barry J Gertz
Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers.
Journal of clinical pharmacology 2001;41(1):107-12.
2000: Jules I Schwartz; K J Bugianesi; David L Ebel; M De Smet; R Haesen; Patrick J Larson; A Ko; Rene Verbesselt; Thomas L Hunt; R Lins; S Lens; Arturo G Porras; J Dieck; Bart Keymeulen; Barry J Gertz
The effect of rofecoxib on the pharmacodynamics and pharmcokinetics of warfarin.
Clinical pharmacology and therapeutics 2000;68(6):626-36.
2000: Anne Van Hecken; Jules I Schwartz; M Depré; Inge De Lepeleire; aimee dallob; Wesley Tanaka; K Wynants; A Buntinx; Jef Arnout; Peggy H Wong; David L Ebel; Barry J Gertz; Paul De Schepper
Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers.
Journal of clinical pharmacology 2000;40(10):1109-20.
2000: Suzanne K Swan; DW Rudy; K C Lasseter; C F Ryan; K L Buechel; Larry Lambrecht; M B Pinto; Stacy C Dilzer; O Obrda; KJ Sundblad; C P Gumbs; David L Ebel; H Quan; Patrick J Larson; Jules I Schwartz; T A Musliner; B J Gertz; D Craig Brater; S L Yao
Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial.
Annals of internal medicine 2000;133(1):1-9.
1999: Jules I Schwartz; C C Chan; S Mukhopadhyay; K J McBride; T M Jones; S Adcock; C Moritz; J Hedges; K Grasing; D Dobratz; R A Cohen; M H Davidson; K A Bachmann; Barry J Gertz
Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans.
Clinical pharmacology and therapeutics 1999;65(6):653-60.
1997: Suresh K Balani; Xin Xu; Vijaya S Pratha; M A Koss; RD Amin; C Dufresne; Randall R Miller; Byron H Arison; George A Doss; M Chiba; A Freeman; Sherry D Holland; Jules I Schwartz; Kenneth C Lasseter; Barry J Gertz; Jon I Isenberg; John D Rogers; Jiunn H Lin; Thomas A Baillie
Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile.
Drug metabolism and disposition: the biological fate of chemicals 1997;25(11):1282-7.
1997: Jules I Schwartz; Wesley Tanaka; D Z Wang; David L Ebel; LA Geissler; aimee dallob; Barry Hafkin; Barry J Gertz
MK-386, an inhibitor of 5alpha-reductase type 1, reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen.
The Journal of clinical endocrinology and metabolism 1997;82(5):1373-7.
1996: Jules I Schwartz; Anne Van Hecken; Paul De Schepper; Inge De Lepeleire; K C Lasseter; E C Shamblen; G A Winchell; Marvin Constanzer; C M Chavez; D Z Wang; D L Ebel; S J Justice; Barry J Gertz
Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men.
The Journal of clinical endocrinology and metabolism 1996;81(8):2942-7.
1995: Jules I Schwartz; K C Yeh; M L Berger; L Tomasko; M E Hoover; D L Ebel; L A Stauffer; R Han; TD Bjornsson
Novel oral medication delivery system for famotidine.
Journal of clinical pharmacology 1995;35(4):362-7.
1994: H Cheng; Jules I Schwartz; C Lin; RD Amin; James R Seibold; K C Lasseter; D L Ebel; D J Tocco; John D Rogers
The bioavailability and nonlinear pharmacokinetics of MK-679 in humans.
Biopharmaceutics & drug disposition 1994;15(5):409-18.
1994: Jules I Schwartz; O L Laskin; C A Meeter; P M Patterson; S H Schneider; K C Lasseter; James R Seibold
Pharmacodynamics of MK-0963, a new 5 alpha-reductase inhibitor: effects on serum androgen concentrations.
Clinical pharmacology and therapeutics 1994;55(1):50-4.
1994: Anne Van Hecken; M Depré; Jules I Schwartz; T B Tjandramaga; G A Winchell; Inge De Lepeleire; J Ng; Paul De Schepper
Plasma concentrations and effect on testosterone metabolism after single doses of MK-0434, a steroid 5 alpha-reductase inhibitor, in healthy subjects.
European journal of clinical pharmacology 1994;46(2):123-6.
1993: Jules I Schwartz; D J Margolskee; TD Bjornsson; V C Williams; J Y Hsieh; C C Lin; John D Rogers
Oral pharmacokinetics and food interaction of the leukotriene D4 receptor antagonist verlukast.
British journal of clinical pharmacology 1993;36(5):464-6.
1993: H Cheng; S C Sutton; J D Pipkin; G M Zentner; John D Rogers; Jules I Schwartz; Yale B Mitchel; K Grasing; M S Schwartz; RD Amin
Evaluation of sustained/controlled-release dosage forms of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors in dogs and humans.
Pharmaceutical research 1993;10(11):1683-7.
1992: P J Pentikainen; M Saraheimo; Jules I Schwartz; RD Amin; M S Schwartz; F Brunner-Ferber; John D Rogers
Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans.
Journal of clinical pharmacology 1992;32(2):136-40.
1990: P J Manning; Richard M Watson; D J Margolskee; V C Williams; Jules I Schwartz; Paul M O'Byrne
Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist.
The New England journal of medicine 1990;323(25):1736-9.
1989: Kenneth Bachmann; Jules I Schwartz; Luis Jauregui
The suitability of carbamazepine as a single-sample probe of human mixed function oxidase activity.
Xenobiotica; the fate of foreign compounds in biological systems 1989;19(7):711-9.
1989: P K Wong; D L Brown; Kenneth Bachmann; R B Forney; C I Hicks; Jules I Schwartz
Optimal dosing of phenytoin: an evaluation of the timing and appropriateness of serum level monitoring.
Hospital formulary 1989;24(4):219-23.
1989: Jules I Schwartz; J L Fink
Legal issues associated with pharmacokinetic software.
American journal of hospital pharmacy 1989;46(1):120-4.
1988: Kenneth Bachmann; Jules I Schwartz; Luis Jauregui
Predicting the ciprofloxacin-theophylline interaction from single plasma theophylline measurements.
British journal of clinical pharmacology 1988;26(2):191-4.
1988: Jules I Schwartz; Luis Jauregui; Kenneth Bachmann; M E Martin; D P Reitberg
Multiple-dose pharmacokinetics of intravenously administered cefoperazone and sulbactam when given in combination to infected, seriously ill, elderly patients.
Antimicrobial agents and chemotherapy 1988;32(5):730-5.
1986: Kenneth Bachmann; Jules I Schwartz; R B Forney; Luis Jauregui; T J Sullivan
Inability of ibuprofen to alter single dose phenytoin disposition.
British journal of clinical pharmacology 1986;21(2):165-9.
1984: K Bachmann; Jules I Schwartz; R B Forney; Luis Jauregui
Single dose phenytoin clearance during erythromycin treatment.
Research communications in chemical pathology and pharmacology 1984;46(2):207-17.
1984: Jules I Schwartz; Kenneth Bachmann
Erythromycin-warfarin interaction.
Archives of internal medicine 1984;144(10):2094.
1984: K Bachmann; Jules I Schwartz; R Forney; A Frogameni; Luis Jauregui
The effect of erythromycin on the disposition kinetics of warfarin.
Pharmacology 1984;28(3):171-6.
1982: Jules I Schwartz; Kenneth Bachmann; L W Bond; V K Mahajan
Impact of cimetidine on the pharmacokinetics of theophylline.
Clinical pharmacy 1982;1(6):534-8.